Physician profile

Laura A Young

Obstetrics & Gynecology · Myrtle Beach, SC

NPI 1497917231

$796.05

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$450.07

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $459.92 2022-2024 Interstim, Intellis Adaptivestim
Duchesnay USA Incorporated $145.16 2019
Heron Therapeutics, INC. $45.63 2023 Zynrelef
Bayer Healthcare Pharmaceuticals INC. $41.77 2023
Organon LLC $38.18 2023-2024 Nexplanon
Astellas Pharma US INC $30.33 2023 Veozah
Exeltis, USA INC. $21.19 2022
Aspira Women'S Health INC $13.87 2023 Ova1

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Laura A Young

$796.05

in general payments reported 2019-2025

Years
2019-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/1117812/laura-a-young

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.